1. | bklein64 | |
2. | srktlk | |
3. | rmekevincannon | |
4. | anthonyr394 | |
5. | plex76 |
1. | bklein64 | |
2. | srktlk | |
3. | rmekevincannon | |
4. | anthonyr394 | |
5. | plex76 |
1. | azweiso6 02/26/2018 Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorization in Europe for the Treatment of X-Linked Hypophosphatemia in Children |
2. | srktlk 01/24/2018 Yeah. |
3. | bklein64 01/08/2018 News - Ultragenyx Announces Positive Interim Topline Results From First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency |
4. | cafereyes 01/29/2018 Ultragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and Executive Vice President |
5. | anthonyr394 01/24/2018 You dont see stocks go up often after an offering, I like it! |
6. | bklein64 02/21/2018 Stifel Nicolaus cuts price target to $74 from $85 |
7. | srktlk 02/21/2018 Morgan Stanley raises PT to $60 from $57 |
8. | bklein64 02/21/2018 Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Update |
9. | azweiso6 05/07/2018 Beats EPS estimates by $0.81. Misses on revenues. |
10. | bklein64 01/24/2018 Ultragenyx Announces Proposed Public Offering of Common Stock |